Clinical trial · Observational
Role of the Pharmacist in Detection of Drug Interactions Before Antitumor Treatment Initiation
Role of the Clinical Pharmacist in an Oncology Ambulatory Center to Prevent Drug Related Problems Before Antitumor Treatment Initiation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this observational study is to evaluate the benefits of a pharmacist integration in an oncology ambulatory center, to prevent drug related problems (in particular drug drug interactions) at antitumor treatment initiation. The hypothesis of this work is that a drug drug interaction will be observed in 30% of cancer patients and will have a major clinical impact in 1% of the cases. The primary endpoint is the prevalence of pharmacist interventions among patients who are going to receive an oral targeted therapy or cancer chemotherapy or immunotherapy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasm | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Prevalence of Pharmacist intervention
- timeFrame
- up to 1 week from date of inclusion
- description
- Percentage of patients whom antitumora treatment or usual treatment has been changed by the pharmacist intervention
Secondary outcomes (7)
- measure
- Detection of Drug -drug interactions
- timeFrame
- up to 1 week from date of inclusion
- description
- Number of drug drug interactions detected
- measure
- Clinical gradation of drug drug interactions
- timeFrame
- One year
- description
- Gradation by an independent experts comity of the clinical impact of prevented drug drug interaction
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * legal age patients * Affiliated to social security or with another insurance system * with a solid tumor * who are going to receive an antitumor treatment (chemotherapy, immunotherapy or oral targeted therapy) Exclusion Criteria: * pregnant women * minor patient
References
Publications (7)
- BACKGROUNDThomas-Schoemann A, Blanchet B, Bardin C, Noe G, Boudou-Rouquette P, Vidal M, Goldwasser F. Drug interactions with solid tumour-targeted therapies. Crit Rev Oncol Hematol. 2014 Jan;89(1):179-96. doi: 10.1016/j.critrevonc.2013.08.007. Epub 2013 Aug 28. PMID 24041628
- BACKGROUNDP. Boudou Rouquette, A. Thomas-Schoemann, A. Chahwakilian et al., Clinical benefit of a one-day multidisciplinary work-up for risk assessment in unfit cancer patients. ESMO congress, abstract 1558; Amsterdam 2013
- BACKGROUNDBonnet C, Boudou-Rouquette P, Azoulay-Rutman E, Huillard O, Golmard JL, Carton E, Noe G, Vidal M, Orvoen G, Chah Wakilian A, Villeminey C, Blanchet B, Alexandre J, Goldwasser F, Thomas-Schoemann A. Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France. Cancer Chemother Pharmacol. 2017 May;79(5):1051-1055. doi: 10.1007/s00280-017-3291-z. Epub 2017 Mar 30. PMID 28361167
- BACKGROUNDLees J, Chan A. Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol. 2011 Dec;12(13):1249-57. doi: 10.1016/S1470-2045(11)70040-7. Epub 2011 Jul 6. PMID 21741307
- BACKGROUNDRiechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007 Apr 18;99(8):592-600. doi: 10.1093/jnci/djk130. PMID 17440160
- BACKGROUNDRuddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009 Jan-Feb;59(1):56-66. doi: 10.3322/caac.20004. PMID 19147869
- RESULTGiraud JS, Korb-Savoldelli V, Perrin G, Jouinot A, Sabatier B, Batista R, Ribault M, De Percin S, Villeminey C, Videau M, Blanchet B, Goldwasser F, Degrassat-Theas A, Thomas-Schoemann A. Clinical and economic impact of pharmacist interventions to identify drug-related problems in multidisciplinary cancer care: a prospective trial. Oncologist. 2025 Aug 4;30(8):oyae213. doi: 10.1093/oncolo/oyae213.